David J Brooks

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8427021/publications.pdf

Version: 2024-02-01

339	46,405	2091	2351
papers	citations	103 h-index	205 g-index

373	373	373	38978
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
2	Capillary function progressively deteriorates in prodromal Alzheimerâ€™s disease: A longitudinal MRI perfusion study. Aging Brain, 2022, 2, 100035.	0.7	4
3	Gaitâ€Related Metabolic Covariance Networks at Rest in Parkinson's Disease. Movement Disorders, 2022, 37, 1222-1234.	2.2	5
4	In vivo vesicular acetylcholine transporter density in human peripheral organs: an [18F]FEOBV PET/CT study. EJNMMI Research, 2022, 12, 17.	1.1	6
5	Spontaneous partial recovery of striatal dopaminergic uptake despite nigral cell loss in asymptomatic MPTP-lesioned female minipigs. NeuroToxicology, 2022, 91, 166-176.	1.4	2
6	In vivo imaging of synaptic SV2A protein density in healthy and striatal-lesioned rats with [11C]UCB-J PET. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 819-830.	2.4	22
7	Progression of sleep disturbances in Parkinsonâ€™s disease: a 5-year longitudinal study. Journal of Neurology, 2021, 268, 312-320.	1.8	30
8	NMDA receptor ion channel activation detected in vivo with [¹⁸F]GE-179 PET after electrical stimulation of rat hippocampus. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1301-1312.	2.4	12
9	Brain Microglial Activation Increased in Glucocerebrosidase (<scp>GBA</scp>) Mutation Carriers without Parkinson's disease. Movement Disorders, 2021, 36, 774-779.	2.2	49
10	Future Imaging in Dementia. Seminars in Nuclear Medicine, 2021, 51, 303-308.	2.5	5
11	Imaging Familial and Sporadic Neurodegenerative Disorders Associated with Parkinsonism. Neurotherapeutics, 2021, 18, 753-771.	2.1	3
12	PET imaging reveals early and progressive dopaminergic deficits after intra-striatal injection of preformed alpha-synuclein fibrils in rats. Neurobiology of Disease, 2021, 149, 105229.	2.1	36
13	Does insulin resistance influence neurodegeneration in non-diabetic Alzheimerâ€™s subjects?. Alzheimer's Research and Therapy, 2021, 13, 47.	3.0	32
14	Monocyte markers correlate with immune and neuronal brain changes in REM sleep behavior disorder. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	35
15	Reduced Synaptic Density in Patients with Lewy Body Dementia: An [<scp>¹¹C</scp>]<scp>UCBâ€J PET</scp> Imaging Study. Movement Disorders, 2021, 36, 2057-2065.	2.2	39
16	Impaired cerebral microcirculation in isolated REM sleep behaviour disorder. Brain, 2021, 144, 1498-1508.	3.7	6
17	Preserved noradrenergic function in Parkinson's disease patients with rest tremor. Neurobiology of Disease, 2021, 152, 105295.	2.1	15
18	Asymmetric Dopaminergic Dysfunction in Brain-First versus Body-First Parkinsonâ€™s Disease Subtypes. Journal of Parkinson's Disease, 2021, 11, 1677-1687.	1.5	34

#	Article	IF	Citations
19	Regional locus coeruleus degeneration is uncoupled from noradrenergic terminal loss in Parkinsonâ€™s disease. Brain, 2021, 144, 2732-2744.	3.7	57
20	The Cholinergic Brain in Parkinson's Disease. Movement Disorders Clinical Practice, 2021, 8, 1012-1026.	0.8	42
21	Impulse control disorders are associated with lower ventral striatum dopamine D3 receptor availability in Parkinson's disease: A [11C]-PHNO PET study. Parkinsonism and Related Disorders, 2021, 90, 52-56.	1.1	4
22	Activated Nâ€methylâ€Dâ€aspartate receptor ion channels detected in focal epilepsy with [¹⁸F]GEâ€179 positron emission tomography. Epilepsia, 2021, 62, 2899-2908.	2.6	3
23	PET Imaging of Translocator Protein Expression in Neurological Disorders. , 2021, , 1021-1040.		2
24	The relationship between flutriciclamide PET uptake and grey matter atrophy in mild cognitive impairment and Alzheimerâ€™s disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
25	Neuroinflammation, amyloid, NFT markers and initial cognitive status predict cognitive decline in MCI patients. Alzheimer's and Dementia, 2021, 17, .	0.4	0
26	Neuroinflammation, functional connectivity and structural network integrity in the Alzheimer's spectrum.. Alzheimer's and Dementia, 2021, 17 Suppl 3, e055970.	0.4	0
27	Low plasma neurofilament light levels associated with raised cortical microglial activation suggest inflammation acts to protect prodromal Alzheimerâ€™s disease. Alzheimer's Research and Therapy, 2020, 12, 3.	3.0	22
28	Tau Tangles in Parkinsonâ€™s Disease: A 2-Year Follow-Up Flortaucipir PET Study. Journal of Parkinson's Disease, 2020, 10, 161-171.	1.5	10
29	In Response to Letter from Fregonara et al. 2019. Molecular Imaging and Biology, 2020, 22, 13-14.	1.3	2
30	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. Lancet Neurology, The, 2020, 19, 951-962.	4.9	254
31	Cortical cholinergic dysfunction correlates with microglial activation in the substantia innominata in REM sleep behavior disorder. Parkinsonism and Related Disorders, 2020, 81, 89-93.	1.1	14
32	Brain-first versus body-first Parkinsonâ€™s disease: a multimodalÂimaging case-control study. Brain, 2020, 143, 3077-3088.	3.7	398
33	Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the <scp>Movement Disorder Society</scp> Multiple System Atrophy Study Group. Movement Disorders Clinical Practice, 2020, 7, 750-762.	0.8	31
34	Microglial activation evaluated using flutriciclamide (11 Fâ€GE180) in subjects with cognitive impairment. Alzheimer's and Dementia, 2020, 16, e045465.	0.4	0
35	Tau formation is associated with microglial activation in more widespread cortical areas than is amyloid deposition. Alzheimer's and Dementia, 2020, 16, e046045.	0.4	0
36	The relationships between neuroinflammation, beta-amyloid and tau deposition in Alzheimerâ€™s disease: a longitudinal PET study. Journal of Neuroinflammation, 2020, 17, 151.	3.1	122

#	Article	IF	Citations
37	EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 1885-1912.	3.3	134
38	18F-GE180, a radioligand for the TSPO protein: not ready for clinical trials in multiple sclerosis. European Journal of Nuclear Medicine and Molecular Imaging, 2020, 47, 2242-2243.	3.3	4
39	Impaired perfusion and capillary dysfunction in prodromal Alzheimer's disease. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12032.	1.2	18
40	Altered sensorimotor cortex noradrenergic function in idiopathic REM sleep behaviour disorder â€“ A PET study. Parkinsonism and Related Disorders, 2020, 75, 63-69.	1.1	27
41	Preclinical PET Studies of [11C]UCB-J Binding in Minipig Brain. Molecular Imaging and Biology, 2020, 22, 1290-1300.	1.3	8
42	Imaging dopamine function and microglia in asymptomatic LRRK2 mutation carriers. Journal of Neurology, 2020, 267, 2296-2300.	1.8	18
43	Influence of microglial activation on structural and functional connectivity in mild cognitive impairment subjects. Alzheimer's and Dementia, 2020, 16, e042990.	0.4	0
44	Ageing and amyloidosis underlie the molecular and pathological alterations of tau in a mouse model of familial Alzheimerâ€™s disease. Scientific Reports, 2019, 9, 15758.	1.6	27
45	Application of advanced brain positron emission tomographyâ€“based molecular imaging for a biological framework in neurodegenerative proteinopathies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 327-332.	1.2	9
46	Abnormal Amyloid Load in Mild Cognitive Impairment: The Effect of Reducing the PiBâ€PET Threshold. Journal of Neuroimaging, 2019, 29, 499-505.	1.0	13
47	Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ€™s disease: study protocol for a randomised controlled trial (ELAD study). Trials, 2019, 20, 191.	0.7	127
48	Attenuation of dopamineâ€induced GABA release in problem gamblers. Brain and Behavior, 2019, 9, e01239.	1.0	13
49	Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter. Molecular Imaging and Biology, 2019, 21, 935-944.	1.3	32
50	Dynamic ¹¹C-PiB PET Shows Cerebrospinal Fluid Flow Alterations in Alzheimer Disease and Multiple Sclerosis. Journal of Nuclear Medicine, 2019, 60, 1452-1460.	2.8	64
51	Microglial activation in early Alzheimer trajectory is associated with higher gray matter volume. Neurology, 2019, 92, e1331-e1343.	1.5	69
52	Widespread microglial activation in multiple system atrophy. Movement Disorders, 2019, 34, 564-568.	2.2	41
53	Comment on â€œIn Vivo [¹⁸F]GE-179 Brain Signal Does Not Show NMDA-Specific Modulation with Drug Challenges in Rodents and Nonhuman Primatesâ€• ACS Chemical Neuroscience, 2019, 10, 768-772.	1.7	11
54	Nigrostriatal proteasome inhibition impairs dopamine neurotransmission and motor function in minipigs. Experimental Neurology, 2018, 303, 142-152.	2.0	27

#	Article	IF	Citations
55	Observations on muscle activity in REM sleep behavior disorder assessed with a semi-automated scoring algorithm. Clinical Neurophysiology, 2018, 129, 541-547.	0.7	11
56	Evaluation of the noradrenergic system in Parkinsonâ€™s disease: an 11C-MeNER PET and neuromelanin MRI study. Brain, 2018, 141, 496-504.	3.7	135
57	Longitudinal diffusion tensor imaging changes in early Parkinsonâ€™s disease: ICICLE-PD study. Journal of Neurology, 2018, 265, 1528-1539.	1.8	35
58	Prevalence of the apolipoprotein E Îµ4 allele in amyloid Î² positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
59	Extrastriatal monoaminergic dysfunction and enhanced microglial activation in idiopathic rapid eye movement sleep behaviour disorder. Neurobiology of Disease, 2018, 115, 9-16.	2.1	35
60	Parametric mapping using spectral analysis for 11C-PBR28 PET reveals neuroinflammation in mild cognitive impairment subjects. European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45, 1432-1441.	3.3	22
61	Association of Cerebral Amyloid-Î² Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
62	MAO-B Inhibitors Do Not Block In Vivo Flortaucipir([18F]-AV-1451) Binding. Molecular Imaging and Biology, 2018, 20, 356-360.	1.3	45
63	Simplifying [18F]GE-179 PET: are both arterial blood sampling and 90-min acquisitions essential?. EJNMMI Research, 2018, 8, 46.	1.1	4
64	The Future of Brain Imaging in Parkinsonâ€™s Disease. Journal of Parkinson's Disease, 2018, 8, S47-S51.	1.5	23
65	The Effect of 40-Hz Light Therapy on Amyloid Load in Patients with Prodromal and Clinical Alzheimerâ€™s Disease. International Journal of Alzheimer's Disease, 2018, 2018, 1-5.	1.1	28
66	Decreased noradrenaline transporter density in the motor cortex of Parkinson's disease patients. Movement Disorders, 2018, 33, 1006-1010.	2.2	33
67	In-vivo staging of pathology in REM sleep behaviour disorder: a multimodality imaging case-control study. Lancet Neurology, The, 2018, 17, 618-628.	4.9	228
68	Role of Neuroinflammation in the Trajectory of Alzheimerâ€™s Disease and in vivo Quantification Using PET. Journal of Alzheimer's Disease, 2018, 64, S339-S351.	1.2	32
69	Motor and <scp>N</scp>onmotor <scp>C</scp>omplications of <scp>L</scp>evodopa: <scp>P</scp>henomenology, <scp>R</scp>isk <scp>F</scp>actors, and <scp>I</scp>maging <scp>F</scp>eatures. Movement Disorders, 2018, 33, 909-919.	2.2	89
70	Microglial activation correlates in vivo with both tau and amyloid in Alzheimerâ€™s disease. Brain, 2018, 141, 2740-2754.	3.7	143
71	In vivo quantification of glial activation in minipigs overexpressing human Î±â€synuclein. Synapse, 2018, 72, e22060.	0.6	15
72	Does inflammation precede tau aggregation in early Alzheimer's disease? A PET study. Neurobiology of Disease, 2018, 117, 211-216.	2.1	46

#	Article	IF	Citations
73	Decreased intestinal acetylcholinesterase in early Parkinson disease. Neurology, 2017, 88, 775-781.	1.5	75
74	Intraâ€•and interâ€network functional alterations in <scp>P</scp>arkinson's disease with mild cognitive impairment. Human Brain Mapping, 2017, 38, 1702-1715.	1.9	49
75	In Vivo cortical tau in Parkinson's disease using 18F-AV-1451 positron emission tomography. Movement Disorders, 2017, 32, 922-927.	2.2	47
76	An early and late peak in microglial activation in Alzheimerâ€™s disease trajectory. Brain, 2017, 140, aww349.	3.7	245
77	Imaging Parkinsonâ€™s disease below the neck. Npj Parkinson's Disease, 2017, 3, 15.	2.5	19
78	Brain inflammation accompanies amyloid in the majority of mild cognitive impairment cases due to Alzheimerâ€™s disease. Brain, 2017, 140, 2002-2011.	3.7	147
79	Longitudinal whole-brain atrophy and ventricular enlargement in nondemented Parkinson's disease. Neurobiology of Aging, 2017, 55, 78-90.	1.5	48
80	Chronic exposure to dopamine agonists affects the integrity of striatal D 2 receptors in Parkinson's patients. NeuroImage: Clinical, 2017, 16, 455-460.	1.4	33
81	[P1â€“130]: DIFFERENT MODELLING APPROACHES FOR TAU TRACER ¹⁸Fâ€AV1451 IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P291.	0.4	0
82	[P2â€“197]: AMYLOID DEPOSITION, TAU AGGREGATION AND MICROGLIAL ACTIVATION CORRELATE WITH VASCULAR BURDEN IN VIVO IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P681.	0.4	1
83	Assessment of neuroinflammation in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a case-control study. Lancet Neurology, The, 2017, 16, 789-796.	4.9	155
84	Sustained striatal dopamine levels following intestinal levodopa infusions in Parkinson's disease patients. Movement Disorders, 2017, 32, 235-240.	2.2	18
85	[P4â€“265]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL. Alzheimer's and Dementia, 2017, 13, P1385.	0.4	0
86	[ICâ€Pâ€074]: LONGITUDINAL DIFFUSION TENSOR IMAGING AS A PREDICTOR OF COGNITIVE DOMAINS DECLINE IN EARLY STAGE PARKINSON's DISEASE: ICICLEâ€PD STUDY. Alzheimer's and Dementia, 2017, 13, P61.	0.4	0
87	[O1â€“12â€“01]: [18F]FLUTEMETAMOL AMYLOID SCANNING IN A PHASE III AMNESTIC MILD COGNITIVE IMPAIRMENT STUDY: ADDITIONAL INFLUENCE OF OTHER BIOMARKERS IN ESTIMATING RISK OF CONVERSION TO PROBABLE ALZHEIMERS DISEASE. Alzheimer's and Dementia, 2017, 13, P221.	0.4	1
88	[ICâ€Pâ€088]: DEEP AND FREQUENT PHENOTYPING STUDY: PET AND MR IMAGING PROTOCOL. Alzheimer's and Dementia, 2017, 13, P71.	0.4	0
89	Imaging synucleinopathies. Movement Disorders, 2016, 31, 814-829.	2.2	33
90	Does Microglial Activation Influence Hippocampal Volume and Neuronal Function in Alzheimerâ€™s Disease and Parkinsonâ€™s Disease Dementia?. Journal of Alzheimer's Disease, 2016, 51, 1275-1289.	1.2	62

#	Article	IF	Citations
91	Using [11C]Ro15 4513 PET to characterise GABA-benzodiazepine receptors in opiate addiction: Similarities and differences with alcoholism. NeuroImage, 2016, 132, 1-7.	2.1	10
92	Imaging Systemic Dysfunction in Parkinsonâ€™s Disease. Current Neurology and Neuroscience Reports, 2016, 16, 51.	2.0	23
93	In vivoimaging of neuromelanin in Parkinsonâ€™s disease using¹⁸F-AV-1451 PET. Brain, 2016, 139, 2039-2049.	3.7	113
94	Hypothalamic volume loss is associated with reduced melatonin output in Parkinson's disease. Movement Disorders, 2016, 31, 1062-1066.	2.2	59
95	Imaging of genetic and degenerative disorders primarily causing Parkinsonism. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 135, 493-505.	1.0	5
96	Kinetic analysis of the translocator protein positron emission tomography ligand [18F]GE-180 in the human brain. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2201-2210.	3.3	70
97	Sleep problems and hypothalamic dopamine D3 receptor availability in Parkinson disease. Neurology, 2016, 87, 2451-2456.	1.5	32
98	Flutriciclamide (¹⁸F-GE180) PET: First-in-Human PET Study of Novel Third-Generation In Vivo Marker of Human Translocator Protein. Journal of Nuclear Medicine, 2016, 57, 1753-1759.	2.8	93
99	Molecular imaging of dopamine transporters. Ageing Research Reviews, 2016, 30, 114-121.	5.0	79
100	Age at onset and Parkinson disease phenotype. Neurology, 2016, 86, 1400-1407.	1.5	245
101	Amyloid pathology and axonal injury after brain trauma. Neurology, 2016, 86, 821-828.	1.5	116
102	Imaging biomarkers in tauopathies. Parkinsonism and Related Disorders, 2016, 22, S26-S28.	1.1	23
103	Thalamic inflammation after brain trauma is associated with thalamo-cortical white matter damage. Journal of Neuroinflammation, 2015, 12, 224.	3.1	60
104	Anticholinergic Load: Is there a Cognitive Cost in Early Parkinsonâ€™s Disease?. Journal of Parkinson's Disease, 2015, 5, 743-747.	1.5	17
105	Imaging neuroinflammation in Alzheimer's disease and other dementias: Recent advances and future directions. Alzheimer's and Dementia, 2015, 11, 1110-1120.	0.4	66
106	Imaging acetylcholinesterase density in peripheral organs in Parkinson's disease with 11C-donepezil PET. Brain, 2015, 138, 653-663.	3.7	135
107	Baseline and longitudinal grey matter changes in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. Brain, 2015, 138, 2974-2986.	3.7	188
108	The role of pallidal serotonergic function in Parkinson's disease dyskinesias: a positron emission tomography study. Neurobiology of Aging, 2015, 36, 1736-1742.	1.5	42

#	Article	IF	Citations
109	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
110	Prevalence of Amyloid PET Positivity in Dementia Syndromes. JAMA - Journal of the American Medical Association, 2015, 313, 1939.	3.8	501
111	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	4.9	4,129
112	Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimerâ€™s disease. Brain, 2015, 138, 3685-3698.	3.7	102
113	Can Studies of Neuroinflammation in a TSPO Genetic Subgroup (HAB or MAB) Be Applied to the Entire AD Cohort?. Journal of Nuclear Medicine, 2015, 56, 707-713.	2.8	30
114	Influence of microglial activation on neuronal function in Alzheimer's and Parkinson's disease dementia. Alzheimer's and Dementia, 2015, 11, 608.	0.4	161
115	Ventral striatal dopamine synthesis capacity is associated with individual differences in behavioral disinhibition. Frontiers in Behavioral Neuroscience, 2014, 8, 86.	1.0	19
116	Characterizing mild cognitive impairment in incident Parkinson disease. Neurology, 2014, 82, 308-316.	1.5	359
117	Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinsonâ€™s disease patients. Journal of Clinical Investigation, 2014, 124, 1340-1349.	3.9	202
118	Increased microglia activation in neurologically asymptomatic HIV-infected patients receiving effective ART. Aids, 2014, 28, 67-72.	1.0	128
119	Genetic impact on cognition and brain function in newly diagnosed Parkinsonâ€™s disease: ICICLE-PD study. Brain, 2014, 137, 2743-2758.	3.7	127
120	Healthâ€related quality of life in early Parkinson's disease: The impact of nonmotor symptoms. Movement Disorders, 2014, 29, 195-202.	2.2	292
121	In Vivo Imaging of Human Acetylcholinesterase Density in Peripheral Organs Using ¹¹C-Donepezil: Dosimetry, Biodistribution, and Kinetic Analyses. Journal of Nuclear Medicine, 2014, 55, 1818-1824.	2.8	40
122	Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid Î²-Amyloid 42. JAMA Neurology, 2014, 71, 1282.	4.5	300
123	Investigating expectation and reward in human opioid addiction with [¹¹ <scp>C</scp>]raclopride <scp>PET</scp>. Addiction Biology, 2014, 19, 1032-1040.	1.4	24
124	Testâ€“retest reproducibility of cannabinoid-receptor type 1 availability quantified with the PET ligand [11C]MePPEP. NeuroImage, 2014, 97, 151-162.	2.1	17
125	Initial Evaluation of 18F-GE-179, a Putative PET Tracer for Activated N-Methyl d-Aspartate Receptors. Journal of Nuclear Medicine, 2014, 55, 423-430.	2.8	68
126	What can biomarkers tell us about cognition in Parkinson's disease?. Movement Disorders, 2014, 29, 622-633.	2.2	61

#	Article	IF	Citations
127	A European multicentre PET study of fibrillar amyloid in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2013, 40, 104-114.	3.3	170
128	Parkinson's Disease â€“ the Debate on the Clinical Phenomenology, Aetiology, Pathology and Pathogenesis. Journal of Parkinson's Disease, 2013, 3, 1-11.	1.5	79
129	The spectrum of nonmotor symptoms in early Parkinson disease. Neurology, 2013, 80, 276-281.	1.5	349
130	Imaging markers for Alzheimer disease. Neurology, 2013, 81, 487-500.	1.5	204
131	Diffusion-weighted imaging and its relationship to microglial activation in parkinsonian syndromes. Parkinsonism and Related Disorders, 2013, 19, 527-532.	1.1	18
132	Microglia, Amyloid, and Glucose Metabolism in Parkinsonâ€™s Disease with and without Dementia. Neuropsychopharmacology, 2013, 38, 938-949.	2.8	202
133	Quantification of opioid receptor availability following spontaneous epileptic seizures: Correction of [11C]diprenorphine PET data for the partial-volume effect. NeuroImage, 2013, 79, 72-80.	2.1	16
134	Binary classification of 18F-flutemetamol PET using machine learning: Comparison with visual reads and structural MRI. NeuroImage, 2013, 64, 517-525.	2.1	56
135	Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology, 2013, 80, 1850-1855.	1.5	95
136	Benefits of putaminal GDNF infusion in Parkinson disease are maintained after GDNF cessation. Neurology, 2013, 81, 1176-1178.	1.5	51
137	The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2013, 84, 657-665.	0.9	80
138	Reference Region Automatic Extraction in Dynamic [¹¹C]PIB. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1725-1731.	2.4	20
139	Bad News for Neuroprotective Therapies in PD?. Journal of Parkinson's Disease, 2013, 3, 271-273.	1.5	1
140	A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need. PLoS ONE, 2013, 8, e57221.	1.1	95
141	Ventral Striatal Dopamine Synthesis Capacity Predicts Financial Extravagance in Parkinsonâ€™s Disease. Frontiers in Psychology, 2013, 4, 90.	1.1	17
142	Serotonin Neuron Loss and Nonmotor Symptoms Continue in Parkinsonâ€™s Patients Treated with Dopamine Grafts. Science Translational Medicine, 2012, 4, 128ra41.	5.8	107
143	11C-PiB PET does not detect PrP-amyloid in prion disease patients including variant Creutzfeldtâ€“Jakob disease: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2012, 83, 340-341.	0.9	8
144	A [¹¹C]Ro15 4513 PET study suggests that alcohol dependence in man is associated with reduced Î±5 benzodiazepine receptors in limbic regions. Journal of Psychopharmacology, 2012, 26, 273-281.	2.0	47

#	Article	IF	Citations
145	The catechol-O-methyltransferase Val158Met polymorphism modulates fronto-cortical dopamine turnover in early Parkinsonâ€™s disease: a PET study. Brain, 2012, 135, 2449-2457.	3.7	56
146	Characterisation of the Contribution of the GABA-Benzodiazepine Î±1 Receptor Subtype to [¹¹C]Ro15-4513 PET Images. Journal of Cerebral Blood Flow and Metabolism, 2012, 32, 731-744.	2.4	33
147	Parkinson's disease: Diagnosis. Parkinsonism and Related Disorders, 2012, 18, S31-S33.	1.1	49
148	Gender-related differences in the burden of non-motor symptoms in Parkinsonâ€™s disease. Journal of Neurology, 2012, 259, 1639-1647.	1.8	211
149	Combination of Biomarkers: PET [¹⁸F]Flutemetamol Imaging and Structural MRI in Dementia and Mild Cognitive Impairment. Neurodegenerative Diseases, 2012, 10, 246-249.	0.8	52
150	Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. Archives of Neurology, 2012, 69, 198.	4.9	349
151	Acute HCV/HIV Coinfection Is Associated with Cognitive Dysfunction and Cerebral Metabolite Disturbance, but Not Increased Microglial Cell Activation. PLoS ONE, 2012, 7, e38980.	1.1	30
152	Can imaging separate multiple system atrophy from Parkinson's disease?. Movement Disorders, 2012, 27, 3-5.	2.2	9
153	The prognostic value of amyloid imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 1207-1219.	3.3	29
154	Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurology, The, 2012, 11, 241-249.	4.9	390
155	Brain monoamine systems in multiple system atrophy: A positron emission tomography study. Neurobiology of Disease, 2012, 46, 130-136.	2.1	34
156	AÎ² Imaging: feasible, pertinent, and vital to progress in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 209-219.	3.3	55
157	Apathy blunts neural response to money in Parkinson's disease. Social Neuroscience, 2011, 6, 653-662.	0.7	38
158	Technical aspects of amyloid imaging for Alzheimer's disease. Alzheimer's Research and Therapy, 2011, 3, 25.	3.0	8
159	Glutamate NMDA receptor dysregulation in Parkinsonâ€™s disease with dyskinesias. Brain, 2011, 134, 979-986.	3.7	177
160	Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal 18F-dopa PET study. NeuroImage, 2011, 56, 1463-1468.	2.1	119
161	Imaging biomarkers in Parkinson's disease. Progress in Neurobiology, 2011, 95, 614-628.	2.8	151
162	The Parkinson Progression Marker Initiative (PPMI). Progress in Neurobiology, 2011, 95, 629-635.	2.8	1,278

#	Article	IF	Citations
163	Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiology of Disease, 2011, 43, 609-615.	2.1	40
164	Milestones in neuroimaging. Movement Disorders, 2011, 26, 868-978.	2.2	9
165	Graftâ€induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Movement Disorders, 2011, 26, 1997-2003.	2.2	151
166	Resting tremor in Parkinson disease: Is the pallidum to blame?. Annals of Neurology, 2011, 69, 229-231.	2.8	8
167	Inflammation after trauma: Microglial activation and traumatic brain injury. Annals of Neurology, 2011, 70, 374-383.	2.8	803
168	Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: A multimodal imaging study. Human Brain Mapping, 2011, 32, 258-270.	1.9	181
169	Carbon-11-Pittsburgh compound B positron emission tomography imaging of amyloid deposition in presenilin 1 mutation carriers. Brain, 2011, 134, 293-300.	3.7	79
170	Persistent Nigrostriatal Dopaminergic Abnormalities in Ex-Users of MDMA (â€˜Ecstasyâ€™): An 18F-Dopa PET Study. Neuropsychopharmacology, 2011, 36, 735-743.	2.8	25
171	An Open-Label, Positron Emission Tomography Study to Assess Adenosine A2A Brain Receptor Occupancy of Vipadenant (BIIB014) at Steady-State Levels in Healthy Male Volunteers. Clinical Neuropharmacology, 2010, 33, 55-60.	0.2	55
172	11C-PiB PET assessment of change in fibrillar amyloid-Î² load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurology, The, 2010, 9, 363-372.	4.9	674
173	Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiology of Disease, 2010, 37, 356-361.	2.1	56
174	Staging of serotonergic dysfunction in Parkinson's Disease: An in vivo 11C-DASB PET study. Neurobiology of Disease, 2010, 40, 216-221.	2.1	213
175	¹⁸Fâ€flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial. Annals of Neurology, 2010, 68, 319-329.	2.8	582
176	Examining Braak's hypothesis by imaging Parkinson's disease. Movement Disorders, 2010, 25, S83-8.	2.2	25
177	Minocycline 1â€year therapy in multipleâ€systemâ€atrophy: Effect on clinical symptoms and [¹¹C](R)â€PK11195 PET (MEMSAâ€trial). Movement Disorders, 2010, 25, 97-107.	2.2	163
178	Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinsonâ€™s Patients with Neural Transplants. Science Translational Medicine, 2010, 2, 38ra46.	5.8	272
179	Imaging dopamine transporters in Parkinsonâ€™s disease. Biomarkers in Medicine, 2010, 4, 651-660.	0.6	33
180	Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain, 2010, 133, 3434-3443.	3.7	273

#	Article	IF	Citations
181	Imaging Approaches to Parkinson Disease. Journal of Nuclear Medicine, 2010, 51, 596-609.	2.8	178
182	GABAergic Dysfunction in Essential Tremor: An¹¹C-Flumazenil PET Study. Journal of Nuclear Medicine, 2010, 51, 1030-1035.	2.8	122
183	In vivo assessment of brain monoamine systems in parkin gene carriers: A PET study. Experimental Neurology, 2010, 222, 120-124.	2.0	25
184	Imaging non-motor aspects of Parkinsonâ€™s disease. Progress in Brain Research, 2010, 184, 205-218.	0.9	25
185	Whole-Body Biodistribution and Radiation Dosimetry of ¹⁸F-GE067: A Radioligand for In Vivo Brain Amyloid Imaging. Journal of Nuclear Medicine, 2009, 50, 818-822.	2.8	200
186	Phase 1 Study of the Pittsburgh Compound B Derivative ¹⁸F-Flutemetamol in Healthy Volunteers and Patients with Probable Alzheimer Disease. Journal of Nuclear Medicine, 2009, 50, 1251-1259.	2.8	273
187	Validation of the freezing of gait questionnaire in patients with Parkinson's disease. Movement Disorders, 2009, 24, 655-661.	2.2	332
188	Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Movement Disorders, 2009, 24, 949-964.	2.2	145
189	Imaging amyloid in Parkinson's disease dementia and dementia with Lewy bodies with positron emission tomography. Movement Disorders, 2009, 24, S742-7.	2.2	84
190	Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: An ¹⁸Fâ€dopa PET progression study. Movement Disorders, 2009, 24, 2260-2266.	2.2	44
191	The risk of exaggerated risk aversionâ€”a life and death struggle for molecular imaging. European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1693-1694.	3.3	11
192	Imaging neurodegeneration in Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 722-729.	1.8	110
193	Brain opioid receptor binding in early abstinence from alcohol dependence and relationship to craving: An [11C]diprenorphine PET study. European Neuropsychopharmacology, 2009, 19, 740-748.	0.3	61
194	Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility. NeuroImage, 2009, 48, 329-338.	2.1	23
195	Recent imaging advances in the diagnosis and management of Parkinson's disease. F1000 Medicine Reports, 2009, 1, .	2.9	6
196	Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinsonâ€™s disease. Journal of Neural Transmission, 2008, 115, 843-849.	1.4	28
197	[11C]Flumazenil PET in Temporal Lobe Epilepsy: Do We Need an Arterial Input Function or Kinetic Modeling?. Journal of Cerebral Blood Flow and Metabolism, 2008, 28, 207-216.	2.4	37
198	Extrastriatal monoamine neuron function in Parkinsonâ€™s disease: An 18F-dopa PET study. Neurobiology of Disease, 2008, 29, 381-390.	2.1	111

#	Article	IF	Citations
199	Microglia, amyloid, and cognition in Alzheimer's disease: An [11C](R)PK11195-PET and [11C]PIB-PET study. Neurobiology of Disease, 2008, 32, 412-419.	2.1	448
200	Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain, 2008, 131, 1294-1302.	3.7	247
201	Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: An in vivo 11C-raclopride PET study. Experimental Neurology, 2008, 214, 112-116.	2.0	101
202	Correlates of local cerebral blood flow (CBF) in normal pressure hydrocephalus patients before and after shuntingâ€"A retrospective analysis of [15O]H2O PET-CBF studies in 65 patients. Clinical Neurology and Neurosurgery, 2008, 110, 369-375.	0.6	70
203	Novel Reference Region Model Reveals Increased Microglial and Reduced Vascular Binding of ¹¹C-(R)-PK11195 in Patients with Alzheimer's Disease. Journal of Nuclear Medicine, 2008, 49, 1249-1256.	2.8	81
204	The Role of Structural and Functional Imaging in Parkinsonian States with a Description of PET Technology. Seminars in Neurology, 2008, 28, 435-445.	0.5	16
205	Technology Insight: imaging neurodegeneration in Parkinson's disease. Nature Clinical Practice Neurology, 2008, 4, 267-277.	2.7	34
206	Neuronal loss associated with cognitive performance in amyotrophic lateral sclerosis: An (¹¹C)â€flumazenil PET study. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2008, 9, 43-49.	2.3	56
207	Brain dopamine response in human opioid addiction. British Journal of Psychiatry, 2008, 193, 65-72.	1.7	64
208	Optimizing levodopa therapy for Parkinson’s disease with levodopa/carbidopa/entacapone: implications from a clinical and patient perspective. Neuropsychiatric Disease and Treatment, 2008, 4, 39.	1.0	93
209	Upregulation of opioid receptor binding following spontaneous epileptic seizures. Brain, 2007, 130, 1009-1016.	3.7	101
210	Volumetric cortical loss in sporadic and familial amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders, 2007, 8, 343-347.	2.3	45
211	Microglial activation in presymptomatic Huntington's disease gene carriers. Brain, 2007, 130, 1759-1766.	3.7	385
212	Carotid body autotransplantation in Parkinson disease: a clinical and positron emission tomography study. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 825-831.	0.9	88
213	Imaging microglial activation in Huntington's disease. Brain Research Bulletin, 2007, 72, 148-151.	1.4	122
214	A systematic comparison of kinetic modelling methods generating parametric maps for [11C]-(R)-PK11195. NeuroImage, 2007, 36, 28-37.	2.1	36
215	Volumes, spatial extents and a probabilistic atlas of the human basal ganglia and thalamus. NeuroImage, 2007, 38, 261-270.	2.1	94
216	Balancing bias, reliability, noise properties and the need for parametric maps in quantitative ligand PET: [11C]diprenorphine testâ€"retest data. NeuroImage, 2007, 38, 82-94.	2.1	46

#	Article	IF	Citations
217	Assessment of Parkinson's disease with imaging. Parkinsonism and Related Disorders, 2007, 13, S268-S275.	1.1	22
218	Imaging Parkinson's disease. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2007, 83, 245-263.	1.0	1
219	Brain opioid receptor binding in early abstinence from opioid dependence. British Journal of Psychiatry, 2007, 191, 63-69.	1.7	68
220	Statistical neuroanatomy of the human inferior frontal gyrus and probabilistic atlas in a standard stereotaxic space. Human Brain Mapping, 2007, 28, 34-48.	1.9	58
221	Reply: Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and parkin-linked Parkinson's disease. Movement Disorders, 2007, 22, 1522-1522.	2.2	0
222	STN Stimulation Alters Pallidalâ€"Frontal Coupling during Response Selection under Competition. Journal of Cerebral Blood Flow and Metabolism, 2007, 27, 1173-1184.	2.4	67
223	Impaired recognition of facial expressions of anger in Parkinson's disease patients acutely withdrawn from dopamine replacement therapy. Neuropsychologia, 2007, 45, 65-74.	0.7	143
224	Imaging Non-Dopaminergic Function in Parkinsonâ€™s Disease. Molecular Imaging and Biology, 2007, 9, 217-222.	1.3	36
225	Cortical involvement in four cases of primary lateral sclerosis using [11C]-flumazenil PET. Journal of Neurology, 2007, 254, 1033-1036.	1.8	42
226	Clinical pharmacology and therapeutic use of COMT inhibition in Parkinson's disease. Journal of Neurology, 2007, 254, IV37-IV48.	1.8	11
227	Imaging in Parkinsonâ€™s Disease: The Role of Monoamines in Behavior. Biological Psychiatry, 2006, 59, 908-918.	0.7	136
228	Imaging the role of dopamine in health and disease Parkinson's disease as a lesion model. Wiener Klinische Wochenschrift, 2006, 118, 570-572.	1.0	9
229	Dopaminergic action beyond its effects on motor function: Imaging studies. Journal of Neurology, 2006, 253, iv8-iv15.	1.8	18
230	GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurology, The, 2006, 5, 200-202.	4.9	35
231	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease, 2006, 21, 404-412.	2.1	982
232	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in progressive supranuclear palsy. Movement Disorders, 2006, 21, 89-93.	2.2	162
233	Nigral degeneration and striatal dopaminergic dysfunction in idiopathic andparkin-linked Parkinson's disease. Movement Disorders, 2006, 21, 299-305.	2.2	18
234	Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with parkin gene mutations. Movement Disorders, 2006, 21, 783-788.	2.2	34

#	Article	IF	Citations
235	New developments of brain imaging for Parkinson's disease and related disorders. Movement Disorders, 2006, 21, 2035-2041.	2.2	34
236	Development of dyskinesias in a 5-year trial of ropinirole and L -dopa. Movement Disorders, 2006, 21, 1844-1850.	2.2	145
237	Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology, 2006, 59, 459-466.	2.8	890
238	Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Annals of Neurology, 2006, 59, 852-858.	2.8	435
239	Amyloid load and cerebral atrophy in Alzheimer's disease: An11C-PIB positron emission tomography study. Annals of Neurology, 2006, 60, 145-147.	2.8	178
240	Imaging of the Parkinsonian Brain in Relation to Restorative Therapy. , 2006, , 119-130.		0
241	Periventricular White Matter Flumazenil Binding and Postoperative Outcome in Hippocampal Sclerosis. Epilepsia, 2005, 46, 944-948.	2.6	34
242	Glial cell lineâ€“derived neurotrophic factor induces neuronal sprouting in human brain. Nature Medicine, 2005, 11, 703-704.	15.2	256
243	Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Annals of Neurology, 2005, 57, 634-641.	2.8	48
244	Chorea associated with thyroxine replacement therapy. Movement Disorders, 2005, 20, 1656-1657.	2.2	35
245	Using [11C]Diprenorphine to Image Opioid Receptor Occupancy by Methadone in Opioid Addiction: Clinical and Preclinical Studies. Journal of Pharmacology and Experimental Therapeutics, 2005, 312, 309-315.	1.3	66
246	Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain, 2005, 128, 2977-2986.	3.7	241
247	Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain, 2005, 128, 1314-1322.	3.7	905
248	The role of opioids in restless legs syndrome: an [11C]diprenorphine PET study. Brain, 2005, 128, 906-917.	3.7	140
249	Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain, 2005, 128, 2786-2796.	3.7	315
250	Imaging studies in drug development: Parkinson's disease. Drug Discovery Today: Technologies, 2005, 2, 317-321.	4.0	2
251	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. NeuroRx, 2005, 2, 226-236.	6.0	97
252	Towards improved test-retest reliability in quantitative ligand PET: [11C]Diprenorphine as an example. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S665-S665.	2.4	2

#	Article	IF	Citations
253	Correlation of regional cerebral amyloid load in Alzheimer's disease, measured with [11C]-PIB pet using spectral analysis and tissue uptake ratios, with Performance on recognition memory tests. Journal of Cerebral Blood Flow and Metabolism, 2005, 25, S591-S591.	2.4	1
254	Positron emission tomography and single-photon emission computed tomography in central nervous system drug development. Neurotherapeutics, 2005, 2, 226-236.	2.1	0
255	Reward Processing in Health and Parkinson's Disease: Neural Organization and Reorganization. Cerebral Cortex, 2004, 14, 73-80.	1.6	44
256	Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain, 2004, 127, 1332-1342.	3.7	104
257	Cognitive and motor effects of dopaminergic medication withdrawal in Parkinsonâ€™s disease. Neuropsychologia, 2004, 42, 1917-1926.	0.7	31
258	The Human Premotor Cortex Is 'Mirror' Only for Biological Actions. Current Biology, 2004, 14, 117-120.	1.8	285
259	Cardiovascular effects of methamphetamine in Parkinson's disease patients. Movement Disorders, 2004, 19, 298-303.	2.2	13
260	In vivo imaging of microglial activation with [11C](R)-PK11195 PET in corticobasal degeneration. Movement Disorders, 2004, 19, 1221-1226.	2.2	128
261	Opioid binding in DYT1 primary torsion dystonia: An11C-diprenorphine PET study. Movement Disorders, 2004, 19, 1498-1503.	2.2	17
262	[123I]AM281 single-photon emission computed tomography imaging of central cannabinoid CB1 receptors before and after Î”9-tetrahydrocannabinol therapy and whole-body scanning for assessment of radiation dose in tourette patients. Biological Psychiatry, 2004, 55, 904-915.	0.7	51
263	Positron emission tomography imaging of transplant function. NeuroRx, 2004, 1, 482-491.	6.0	19
264	Neuroimaging in Parkinsonâ€™s disease. NeuroRx, 2004, 1, 243-254.	6.0	82
265	Safety and tolerability of COMT inhibitors. Neurology, 2004, 62, S39-46.	1.5	58
266	Neuroimaging in Parkinsonâ€™s disease. Neurotherapeutics, 2004, 1, 243-254.	2.1	0
267	Positron emission tomography imaging of transplant function. Neurotherapeutics, 2004, 1, 482-491.	2.1	0
268	Monoamine neuron innervation of the normal human brain: an 18F-DOPA PET study. Brain Research, 2003, 982, 137-145.	1.1	84
269	Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. Human Brain Mapping, 2003, 19, 224-247.	1.9	1,040
270	Plasticity of the nigropallidal pathway in Parkinson's disease. Annals of Neurology, 2003, 53, 206-213.	2.8	152

#	Article	IF	Citations
271	Imaging end points for monitoring neuroprotection in Parkinson's disease. Annals of Neurology, 2003, 53, S110-S119.	2.8	49
272	Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Annals of Neurology, 2003, 53, 647-653.	2.8	149
273	Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Annals of Neurology, 2003, 54, 93-101.	2.8	820
274	Direct brain infusion of glial cell lineâ€“derived neurotrophic factor in Parkinson disease. Nature Medicine, 2003, 9, 589-595.	15.2	1,244
275	Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain, 2003, 126, 1127-1135.	3.7	201
276	Grey and white matter flumazenil binding in neocortical epilepsy with normal MRI. A PET study of 44 patients. Brain, 2003, 126, 1300-1318.	3.7	87
277	Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain, 2003, 126, 312-325.	3.7	90
278	PET Studies on the Function of Dopamine in Health and Parkinson's Disease. Annals of the New York Academy of Sciences, 2003, 991, 22-35.	1.8	34
279	Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain, 2002, 125, 2248-2256.	3.7	141
280	Increased dopamine tone during meditation-induced change of consciousness. Cognitive Brain Research, 2002, 13, 255-259.	3.3	300
281	Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: An18F-dopa PET study. Annals of Neurology, 2002, 52, 849-853.	2.8	192
282	An imaging study of parkinsonism among African-Caribbean and Indian London communities. Movement Disorders, 2002, 17, 1321-1328.	2.2	15
283	Implementation and application of a brain template for multiple volumes of interest. Human Brain Mapping, 2002, 15, 165-174.	1.9	87
284	18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse, 2002, 43, 201-207.	0.6	100
285	Dyskinesias following neural transplantation in Parkinson's disease. Nature Neuroscience, 2002, 5, 627-628.	7.1	424
286	DIAGNOSIS AND MANAGEMENT OF ATYPICAL PARKINSONIAN SYNDROMES. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 72, i10-i16.	0.9	43
287	In-vivo measurement of activated microglia in dementia. Lancet, The, 2001, 358, 461-467.	6.3	983
288	Depression in ParkinsonÊ¼s disease. Current Opinion in Neurology, 2001, 14, 465-470.	1.8	43

#	Article	IF	Citations
289	Updated guidelines for the management of Parkinson's disease. British Journal of Hospital Medicine, 2001, 62, 456-470.	0.3	25
290	International Medical Workshop covering progressive supranuclear palsy, multiple system atrophy and cortico basal degeneration. Movement Disorders, 2001, 16, 382-395.	2.2	6
291	Resting regional cerebral glucose metabolism in advanced Parkinson's disease studied in theoff andon conditions with [18F]FDG-PET. Movement Disorders, 2001, 16, 1014-1022.	2.2	109
292	Global Increase in Cortical Opioid Binding Potential with Aging: In Vivo Quantification with 11C diprenorphine PET. Psychogeriatrics, 2001, 1, 309-316.	0.6	1
293	Chapter 14 Non-invasive in vivo imaging of transplant function. Progress in Brain Research, 2000, 127, 321-332.	0.9	4
294	Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Annals of Neurology, 2000, 48, 689-695.	2.8	246
295	Health-related quality of life following bilateral intrastriatal transplantation in Parkinson's disease. Movement Disorders, 2000, 15, 224-229.	2.2	47
296	Research goals in progressive supranuclear palsy. Movement Disorders, 2000, 15, 446-458.	2.2	29
297	Imaging basal ganglia function. Journal of Anatomy, 2000, 196, 543-554.	0.9	25
298	A Five-Year Study of the Incidence of Dyskinesia in Patients with Early Parkinson's Disease Who Were Treated with Ropinirole or Levodopa. New England Journal of Medicine, 2000, 342, 1484-1491.	13.9	1,467
299	Identification of the Cerebral Loci Processing Human Swallowing With H₂¹⁵O PET Activation. Journal of Neurophysiology, 1999, 81, 1917-1926.	0.9	338
300	Huntington's disease progression. Brain, 1999, 122, 2353-2363.	3.7	193
301	Mapping the network for planning: a correlational PET activation study with the Tower of London task. Brain, 1999, 122, 1973-1987.	3.7	368
302	Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nature Neuroscience, 1999, 2, 1137-1140.	7.1	663
303	The Effect of the Nitric Oxide Synthase Inhibitor L-NMMA on Basal CBF and Vasoneuronal Coupling in Man: A PET Study. Journal of Cerebral Blood Flow and Metabolism, 1999, 19, 673-678.	2.4	57
304	A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease. Metabolic Brain Disease, 1999, 14, 45-55.	1.4	50
305	The role of inheritance in sporadic Parkinson's disease: Evidence from a longitudinal study of dopaminergic function in twins. Annals of Neurology, 1999, 45, 577-582.	2.8	306
306	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology. , 1999, 9, 247-254.		96

#	Article	IF	Citations
307	Association of abnormal cerebellar activation with motor learning difficulties in dyslexic adults. Lancet, The, 1999, 353, 1662-1667.	6.3	277
308	Temporally-specific retrograde amnesia in two cases of discrete bilateral hippocampal pathology. , 1999, 9, 247.		1
309	Advances in the understanding of early Huntington's disease using the functional imaging techniques of PET and SPET. Trends in Molecular Medicine, 1998, 4, 532-539.	2.6	40
310	In vivo [11C] flumazenil-PET correlates with ex vivo [3H] flumazenil autoradiography in hippocampal sclerosis. Annals of Neurology, 1998, 43, 618-626.	2.8	69
311	Ropinirole in the treatment of early Parkinson's disease: A 6-month interim report of a 5-year levodopa-controlled study. Movement Disorders, 1998, 13, 39-45.	2.2	262
312	Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6-month interim report of a 3-year study. Movement Disorders, 1998, 13, 46-51.	2.2	135
313	Increased activation of frontal areas during arm movement in idiopathic torsion dystonia. Movement Disorders, 1998, 13, 309-318.	2.2	97
314	Dopamine agonists and neuroprotection in parkinson's disease. Annals of Neurology, 1998, 44, S167-74.	2.8	108
315	Prefrontal cortex activity in people with schizophrenia and control subjects. British Journal of Psychiatry, 1998, 172, 316-323.	1.7	110
316	The effect of movement frequency on cerebral activation: a positron emission tomography study. Journal of the Neurological Sciences, 1997, 151, 195-205.	0.3	83
317	Central Benzodiazepine/gamma-Aminobutyric AcidA Receptors in Idiopathic Generalized Epilepsy: An [11C]Flumazenil Positron Emission Tomography Study. Epilepsia, 1997, 38, 1089-1097.	2.6	79
318	11C-Diprenorphine Binding in Huntington's Disease: A Comparison of Region of Interest Analysis with Statistical Parametric Mapping. Journal of Cerebral Blood Flow and Metabolism, 1997, 17, 943-949.	2.4	73
319	Stereotactic thalamotomy in tremor-dominant Parkinson's disease: An H215O PET motor activation study. Annals of Neurology, 1997, 41, 108-111.	2.8	62
320	Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Annals of Neurology, 1997, 42, 95-107.	2.8	331
321	Cerebral glucose metabolism in corticobasal degeneration: Comparison with progressive supranuclear palsy and normal controls. Movement Disorders, 1997, 12, 691-696.	2.2	55
322	Parkinsonism associated with acute intracranial hematomas: An [18F]dopa positron-emission tomography study. Movement Disorders, 1997, 12, 1035-1038.	2.2	36
323	Evaluation of [11C]RTI-121 as a selective radioligand for PET studies of the dopamine transporter. Nuclear Medicine and Biology, 1996, 23, 377-384.	0.3	17
324	Benzodiazepine-GABAA Receptors in Idiopathic Generalized Epilepsy Measured with [11C]Flumazenil and Positron Emission Tomography. Epilepsia, 1995, 36, 113-121.	2.6	47

#	Article	IF	Citations
325	Benzodiazepine-GABAA Receptor Binding During Absence Seizures. Epilepsia, 1995, 36, 592-599.	2.6	28
326	L-Dihydroxyphenylalanine and its decarboxylase: New ideas on their neuroregulatory roles. Movement Disorders, 1995, 10, 241-249.	2.2	52
327	Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum, quantified using PET. Synapse, 1995, 21, 45-53.	0.6	91
328	Evidence for long-term survival and function of dopaminergic grafts in progressive Parkinson's disease. Annals of Neurology, 1994, 35, 172-180.	2.8	412
329	Nigrostriatal function in vitamin E deficiency: Clinical, experimental, and positron emission tomographic studies. Annals of Neurology, 1994, 35, 298-303.	2.8	48
330	Quantitation of Carbon-11-labeled raclopride in rat striatum using positron emission tomography. Synapse, 1992, 12, 47-54.	0.6	198
331	Core assessment program for intracerebral transplantations (CAPIT). Movement Disorders, 1992, 7, 2-13.	2.2	874
332	PET: Motor function and dysfunction. Movement Disorders, 1992, 7, 20-20.	2.2	1
333	Transplantation of fetal dopamine neurons in Parkinson's disease: PET {18F}6-L-fluorodopa studies in two patients with putaminal implants. Annals of Neurology, 1992, 31, 166-173.	2.8	304
334	The clinical role of PET in cerebrovascular disease. Neurosurgical Review, 1991, 14, 91-96.	1.2	11
335	A Two-Compartment Description and Kinetic Procedure for Measuring Regional Cerebral [¹¹C]Nomifensine Uptake Using Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1990, 10, 307-316.	2.4	73
336	Measurement of Regional Cerebral pH in Human Subjects Using Continuous Inhalation of 11CO2 and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 458-465.	2.4	58
337	Quantitative Measurement of Bloodâ€"Brain Barrier Permeability Using Rubidium-82 and Positron Emission Tomography. Journal of Cerebral Blood Flow and Metabolism, 1984, 4, 535-545.	2.4	86
338	Positron emission tomography in the study of cerebral tumours. Neurosurgical Review, 1984, 7, 253-258.	1.2	9
339	Microglial Activation Is Increased in Glucocerebrosidase (GBA1) Mutation Carriers: A Cross-Sectional PET Study. SSRN Electronic Journal, 0, , .	0.4	0